|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005516,
umls-concept:C0006826,
umls-concept:C0027625,
umls-concept:C0027651,
umls-concept:C0034897,
umls-concept:C0205065,
umls-concept:C0205225,
umls-concept:C0205322,
umls-concept:C0220825,
umls-concept:C0221908,
umls-concept:C0282460,
umls-concept:C0442034,
umls-concept:C1512288,
umls-concept:C1707080,
umls-concept:C2603343,
umls-concept:C2746052
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-9-12
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Patients with persistent/recurrent epithelial ovarian cancer/primary peritoneal cancer (EOC/PPC) have limited treatment options. AKT and PI3K pathway activation is common in EOC/PPC, resulting in constitutive activation of downstream mTOR. The GOG conducted a phase II evaluation of efficacy and safety for the mTOR inhibitor, temsirolimus in EOC/PPC and explored circulating tumor cells (CTC) and AKT/mTOR/downstream tumor markers.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/CCND1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin D1,
http://linkedlifedata.com/resource/pubmed/chemical/MTOR protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-akt,
http://linkedlifedata.com/resource/pubmed/chemical/Sirolimus,
http://linkedlifedata.com/resource/pubmed/chemical/TOR Serine-Threonine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/temsirolimus
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1095-6859
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Published by Elsevier Inc.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
123
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
19-26
|
|
pubmed:meshHeading |
pubmed-meshheading:21752435-Adult,
pubmed-meshheading:21752435-Aged,
pubmed-meshheading:21752435-Aged, 80 and over,
pubmed-meshheading:21752435-Antineoplastic Agents,
pubmed-meshheading:21752435-Cyclin D1,
pubmed-meshheading:21752435-Disease-Free Survival,
pubmed-meshheading:21752435-Female,
pubmed-meshheading:21752435-Humans,
pubmed-meshheading:21752435-Middle Aged,
pubmed-meshheading:21752435-Neoplasms, Glandular and Epithelial,
pubmed-meshheading:21752435-Neoplastic Cells, Circulating,
pubmed-meshheading:21752435-Ovarian Neoplasms,
pubmed-meshheading:21752435-Peritoneal Neoplasms,
pubmed-meshheading:21752435-Proto-Oncogene Proteins c-akt,
pubmed-meshheading:21752435-Sirolimus,
pubmed-meshheading:21752435-TOR Serine-Threonine Kinases,
pubmed-meshheading:21752435-Tumor Markers, Biological,
pubmed-meshheading:21752435-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.
|
|
pubmed:affiliation |
University of Colorado Denver, Aurora, CO 80045, USA. kian.behbakht@ucdenver.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
